Evolent Health Reports Material Agreements & Equity Sales
Ticker: EVH · Form: 8-K · Filed: Aug 21, 2025 · CIK: 1628908
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
Related Tickers: EVH
TL;DR
EVH entered material agreements and sold equity on 8/18. Check the 8-K for details.
AI Summary
Evolent Health, Inc. filed an 8-K on August 21, 2025, reporting on several key events that occurred on August 18, 2025. These include entering into a material definitive agreement, creating a direct financial obligation, and unregistered sales of equity securities. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions by Evolent Health, including new financial obligations and equity transactions, which could impact its financial structure and shareholder equity.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Evolent Health, Inc. (company) — Registrant
- August 18, 2025 (date) — Date of earliest event reported
- August 21, 2025 (date) — Date of Report
FAQ
What specific material definitive agreement did Evolent Health enter into?
The filing indicates the entry into a material definitive agreement but does not specify the details of the agreement itself within the provided text.
What is the nature of the direct financial obligation created by Evolent Health?
The filing states that a direct financial obligation was created, but the specific details of this obligation are not provided in the excerpt.
What were the circumstances of the unregistered sales of equity securities?
The filing reports unregistered sales of equity securities, but the terms, volume, and recipients of these sales are not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these documents is not detailed in the provided text.
What is Evolent Health's principal executive office address?
Evolent Health's principal executive offices are located at 1812 North Moore Street, Suite 1705, Arlington, Virginia, 22209.
Filing Stats: 1,531 words · 6 min read · ~5 pages · Grade level 10.6 · Accepted 2025-08-21 17:04:20
Key Financial Figures
- $0.01 — tock of Evolent Health, Inc., par value $0.01 per share EVH New York Stock Exchan
- $145.0 million — ), relating to the issuance and sale of $145.0 million aggregate principal amount of its 4.50%
- $21.75 million — option to purchase up to an additional $21.75 million aggregate principal amount of notes, wh
- $166.75 million — urred on August 21, 2025 and a total of $166.75 million aggregate principal amount of notes wer
- $161.2 m — f par for net proceeds of approximately $161.2 million, after deducting fees and estimat
- $167.4 million — , the Company repurchased approximately $167.4 million aggregate principal amount of its 1.50%
- $167.6 million — senior notes due 2025 for approximately $167.6 million in cash in note repurchases entered int
- $40.0 million — Company also repurchased approximately $40.0 million of shares of the Company's Class A comm
- $1,000 — the Company's Class A common stock per $1,000 principal amount of notes, which is equ
- $13.53 — itial conversion price of approximately $13.53 per share of the Company's Class A comm
Filing Documents
- d72742d8k.htm (8-K) — 35KB
- d72742dex41.htm (EX-4.1) — 606KB
- d72742dex101.htm (EX-10.1) — 247KB
- g72742g0821092637655.jpg (GRAPHIC) — 2KB
- g72742g0821092637921.jpg (GRAPHIC) — 2KB
- g72742g0821092638071.jpg (GRAPHIC) — 2KB
- g72742g0821092638199.jpg (GRAPHIC) — 2KB
- g72742g0821092638347.jpg (GRAPHIC) — 2KB
- g72742g0821092638502.jpg (GRAPHIC) — 3KB
- g72742g0821114418535.jpg (GRAPHIC) — 5KB
- 0001193125-25-185388.txt ( ) — 1212KB
- evh-20250818.xsd (EX-101.SCH) — 3KB
- evh-20250818_lab.xml (EX-101.LAB) — 18KB
- evh-20250818_pre.xml (EX-101.PRE) — 11KB
- d72742d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 4.1 Indenture, dated as of August 21, 2025, between Evolent Health, Inc. and U.S. Bank Trust Company, National Association, as trustee. 4.2 Form of 4.50% Convertible Senior Notes due 2031 (included as Exhibit A to Exhibit 4.1) 10.1 Purchase Agreement, dated August 18, 2025, by and between Evolent Health, Inc. and Oppenheimer & Co. Inc. 104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOLENT HEALTH, INC. Date: August 21, 2025 By: /s/ Jonathan D. Weinberg Name: Jonathan D. Weinberg Title: General Counsel and Secretary